تسجيل الدخول

تسجيل

γδ T-Cells

المؤلف:  Armin Ghobadi & John F. DiPersio

المصدر:  Gene and Cellular Immunotherapy for Cancer

الجزء والصفحة:  p60-61

2026-08-17

13

Although αβ T-cells make up 95% of the T-cell population and have been most heavily studied over the years, the less common γδ T-cell has gained attraction as a CAR substrate for a variety of reasons. The γδ TCR does not utilize MHC molecules for antigen recognition, and is much less likely to cause GVHD if used in an allogeneic setting. γδ T-cells can naturally exert antitumor cytotoxicity without a CAR, demonstrating they have the appropriate machinery for tumor killing. They have a natural predilection for tissue residence, which may provide an advantage in tumors in which tissue infiltration by T-cells is a limitation, such as most solid tumors. CAR modified γδ T-cells can expand nearly 100-fold in the course of 2 weeks in vitro, and exert target-specific killing. Clinical trials underway testing CAR γδ T-cells in solid tumors (NCT04107142) and liquid tumors (NCT02656147, NCT03885076) will provide insight into whether these types of CAR T-cells are safe and feasible, and may provide some insight into potential for efficacy in humans.